Assessment of a self-assembling peptide gel, SPG-178, in providing a clear operative field for trabeculectomy surgery for glaucoma in an animal model by Matsushita, Kenji et al.
1Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11326  | https://doi.org/10.1038/s41598-020-68171-3
www.nature.com/scientificreports
Assessment of a self‑assembling 
peptide gel, SPG‑178, 
in providing a clear operative 
field for trabeculectomy surgery 
for glaucoma in an animal model
Kenji Matsushita1*, Rumi Kawashima1, Koji Uesugi1,2, Haruka Okada2, Hirokazu Sakaguchi3, 
Andrew J. Quantock4 & Kohji Nishida1,5*
The presence of blood during ophthalmic surgery is problematic, as it can obstruct a surgeon’s view of 
the operative field. This is particularly true when performing trabeculectomy surgery to enhance ocular 
fluid outflow and reduce intraocular pressure as a treatment for glaucoma, one of the most common 
vision loss conditions worldwide. In this study, we investigated the performance of a transparent, self‑
assembling peptide gel (SPG‑178) and its ability to maintain visibility during trabeculectomy surgery. 
Unlike the hyaluronic acid gel commonly used in ophthalmic surgery, SPG‑178 did not permit the 
ingress of blood into the gel itself. Rather, it forced blood to flow peripherally to the gel. Moreover, if 
bleeding occurred under the SPG‑178 gel, perfusion with saline was able to effectively flush the blood 
away along the interface between the SPG‑178 and the ocular tissue (in this case scleral) to clear the 
surgical field of view. In experimental trabeculectomy surgeries with mitomycin C used as an adjuvant, 
there were no differences in the postoperative recovery of intraocular pressure or bleb morphology 
with or without the use of SPG‑178. SPG‑178, therefore, when used in a gel formulation, represents 
a new material for use in intraocular surgery to ensure a clear operative field with likely beneficial 
treatment outcomes.
The control of bleeding during ophthalmic surgery is key if we are to optimize intraoperative visibility and 
enhance the surgical  outcome1,2. To help achieve this, procedures such as heat coagulation and ligation have 
been performed, and the development of new hemostatic agents and devices is being  investigated3–6. Ophthalmic 
surgery is particularly susceptible to intraoperative bleeding because there are many arterioles present in the eye, 
and attempts at achieving hemostasis have met with limited success. Techniques such as thermo-coagulation, 
for example, invariably result in the constriction of ocular tissues—especially the conjunctiva and sclera—which 
can have a detrimental impact on the  surgery7,8.
Glaucoma is a major reason for irreversible vision loss. Indeed, it is currently ranked as a top cause of 
blindness worldwide, with its prevalence being closely monitored by the World Health  Organization9,10. In cases 
of glaucoma in which drug treatment is inappropriate owing to side effects of the medication, or in patients who 
experience an insufficient reduction of intraocular pressure (IOP), intraocular surgery can be performed to 
reduce the  IOP8. Prior to glaucoma surgery patients often receive IOP-lowering eye-drops. This has unwanted 
consequences, however, because the eye drops are vasoactive and dilate ocular surface blood vessels to exacerbate 
the likelihood of bleeding. Good intraoperative visibility is an important issue for glaucoma surgery because 
open
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it may detrimentally affect the surgical  outcome8. Here, we investigate the use of a self-assembling peptide gel 
(SPG-178) as a novel material, which safeguards visibility during glaucoma surgery without the need for heat 
coagulation and the deleterious effects that accompany this.
The SPG-178 is a peptide consisting of 13 amino acid residues with the sequence RLDLRLALRLDLR, where R, 
L, D, and A refer to arginine, leucine, aspartic acid, and alanine,  respectively11. The peptide forms an antiparallel 
beta sheet structure in aqueous solution via electrostatic interactions (Fig. 1) and a gel, SPG-178, by creating a 
three-dimensional network of fibers. SPG-178 is neutral and transparent, and when it comes into contact with 
salt or a bodily fluid such as blood, it forms a  boundary4 as it  hardens11. These characteristics have been studied 
in various medical  fields12–15. Taking advantage of the unique properties of the SPG-178, herein we report its 
use to ensure intraoperative visibility applicable to a wide range of ophthalmic operations, not least of which is 
surgery for glaucoma that, as mentioned, is prone to excessive bleeding.
Results
The SPG‑178 prohibits the ingress of blood. The diffusion of blood into Viscoat, a hyaluronic acid gel 
commonly used for ophthalmic surgery, and into the SPG-178 gel was measured and found to be significantly 
suppressed in the SPG-178 case when compared to that of Viscoat (p = 0.002 (repeated ANOVA), p = 0.01 
(0 min), p < 0.01 (2, 4, 6, 8, and 10 min after the immersion of each material in 2 ml of blood) (unpaired Student’s 
t test)) (Fig. 1).
Figure 1.  The ingress of blood into the SPG-178 gel. (a) The ability of SPG-178 and Viscoat hyaluronic acid to 
allow the inward diffusion of blood after immersion for 2 min in 2 ml of blood. (b) Area occupied by blood in 
SPG-178 (black diamond) and Viscoat (black square) (p = 0.002 (repeated ANOVA), *p = 0.01 (0 min); **p < 0.01 
(2, 4, 6, 8, 10 min) by unpaired Student’s t test). The error bars represent the standard deviation of the means 
(SDs, n = 3). (c) The peptide forms an antiparallel beta sheet structure in an aqueous solution by electrostatic 
interaction and forms one fiber.
3Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11326  | https://doi.org/10.1038/s41598-020-68171-3
www.nature.com/scientificreports/
The SPG‑178 excludes blood and maintains visibility of the adjacent tissue in vivo. To evaluate 
the ability of the SPG-178 gel to maintain the visibility in an eye wound in  vivo, partial-depth, flap-shaped 
scleral incisions (scleral flaps) were created in the eyes of buphthalmos rabbits. When SPG-178 was applied to 
the sclera, it excluded the blood and secured the visibility of the operative field within 30 s (Fig. 2a). At this time-
point, the area occupied by blood on the sclera was significantly less in the SPG-178 application group compared 
to the non-application group (p < 0.05, [Mann–Whitney U test]) (Fig. 2b). Furthermore, when new bleeding 
occurred under the SPG-178 gel created by an incision through the gel, saline perfusion was able to flush the 
blood away from the operative field within a few seconds, along an exit-route formed between the interface of 
the SPG-178 gel and the scleral bed, which was then clearly visible (Fig. 2c,d).
SPG‑178 and its use for experimental trabeculectomy. To examine the potential applicability of 
SPG-178 for glaucoma surgery, 16 rabbits underwent a trabeculectomy performed with SPG-178 and mitomycin 
C (group SM; n = 5) or with mitomycin C alone (group M; n = 5). A control group (group C) of six rabbits 
received a trabeculectomy without either mitomycin C or SPG-178. After surgery, IOP was significantly lower in 
groups SM and M than in control group C throughout the postoperative day 7–28 period [p < 0.001 (ANOVA), 
p < 0.01 (Dunnett’s test)] (Fig. 3a). The height of the bleb was also significantly larger in groups SM and M than 
in group C [p = 0.004 (ANOVA), p < 0.01 (Dunnett’s test)] on postoperative day 28 (Fig. 3b–d). No complications 
Figure 2.  Visibility of the operative field adjacent to SPG-178. (a) Visibility of the scleral bed (white dotted line) 
at each time point with/without SPG-178. (b) The area of the scleral bed occupied by blood 30 s after surgery 
with/without SPG-178 (*p < 0.05 by Mann–Whitney U’s test). The error bars represent the SDs (n = 4). (c) 
Representative image of perfusion insertion, with the yellow arrow indicating new bleeding that occurred under 
the SPG-178 gel. Perfusion insertion with a needle placed between SPG-178 and the sclera resulted in clear 
visibility under the gel. Blue arrows indicate blood discharged outside the SPG-178 gel. (d) Schematic of the 
dispersal of blood from under SPG-178 via the flow of saline between the gel and the sclera.
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Figure 3.  Experimental trabeculectomy with SPG-178. (a) Time course of intraocular pressure (IOP) change 
after a trabeculectomy operation in the SM group (black circles), M group (black squares), and control C group 
(black triangles). The IOP was significantly lower in the SM and M groups compared to IOP in the C group 
between 7 and 28 days (p < 0.001 by ANOVA, **p < 0.01; and n.s., not significant by Dunnett’s test). (b, c) A 
bleb (white arrow) was formed at postoperative day 28 in the SM, M, and C groups as seen by both slit-lamp 
observation (b) and optical coherence tomography (c). (d) The height of the bleb at postoperative day 28 was 
significantly greater in the SM and M groups compared to the C group (p = 0.004 by ANOVA, **p < 0.01; and 
n.s., not significant by Dunnett’s test). Error bars represent SDs [n = 6 (C group), n = 5 (M and SM groups)]. (e) 
Histology of the sclera on postoperative day 28 in the SM and M groups. The arrowhead indicates the cornea, 
the arrow the iridectomy wound, the dotted arrow the scleral flap, and the dotted line the bleb. Scale bar = 1 mm. 
(f, g) Slit lamp observation after injection of SPG-178 into the anterior chamber. The SPG-178 became cloudy, 
but the cornea remained clear. (f) 4 h after its insertion, (g) 2 weeks after the operation. The white arrowhead 
indicates cloudy SPG-178 adhered to the corneal endothelial surface.
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were observed in any of the groups, and based on histological analyses no differences were observed between 
groups SM and M (Fig. 3e), suggesting that, in the short-term at least, SPG-178 is suitable for use in intraocular 
surgery.
During trabeculectomy surgery, there is a risk of the inadvertent entry of surgical materials into the anterior 
chamber of the eye, which separates the cornea and lens. To assess the potential effect such an eventuality with 
SPG-178, small amounts of the gel were inserted into the anterior chamber close to the corneal endothelium 
and next to the lens using a 26-gauge needle. As a sham control, a 26-gauge needle was briefly placed in contact 
with the corneal endothelium and the lens. Four hours after its insertion into the anterior chamber, the SPG-178 
had become cloudy and visible, and one day later it was seen to be attached to both the corneal endothelium 
and the anterior surface of the lens (Fig. 3f). The reason for the cloudiness of the SPG-178 in the anterior 
chamber is believed to be because of an aggregation caused by the electrostatic interaction between charged 
SPG-178 and sodium, chloride, and protein in the aqueous  humor14. The SPG-178 that was attached to the 
surface of the corneal endothelium was turbid and white in colour and kept its shape until five weeks after the 
operation (Fig. 3g). On the lens, however, the cloudy SPG-178 faded and its outline became unclear one week 
postoperatively. A week later the gel was barely observable on the lens, and it was not seen at all subsequent to 
this. In the control sham-operated group, a slight trace of the needle tip placement area was observed the day 
after surgery, which disappeared by the second week postoperatively. No abnormalities were observed in the 
anterior segment in the five weeks following surgery.
Discussion
Materials and techniques to effectively secure intraoperative visibility during eye surgery are sought by the 
ophthalmic community. Here, we show how an SPG-178 gel not only prohibited the ingress of blood into the 
body of the gel itself, but also discharged existing blood from areas of the eye to which it was applied. Suppression 
of blood ingress is due to the fact that a partially impermeable interface is formed between the SPG-178 gel and 
blood once they come into  contact4. In contrast, hyaluronic acid gels, which are commonly used in ophthalmic 
surgery, do not form a barrier to blood at their surface, thus allowing blood to diffuse into the gel. The suppression 
of blood ingress, accompanied by the high transparency of the gel itself, identifies SPG-178 as a valuable material 
for use in intraocular surgery ensuring good visibility in the operative field in regions of the eye to which it will 
be applied.
In this study, the hemostatic effect of the SPG-178 was weak, and when bleeding occurred under the gel, the 
blood soon dispersed. The rabbits used in this study developed buphthalmos, which meant that they had high 
blood pressure locally in their eyes. Thus, the hemostatic effect of SPG-178 cannot be fully appreciated by the 
current experiments, unlike in a previous  study4 involving rats. Our investigations show that by perfusing saline 
under the SPG-178 gel, blood that had pooled under the gel could be transferred away without the collapse of the 
gel (Supplementary Video). The concept behind this is that the action of perfusing saline between SPG-178 and 
the scleral bed on which it sits results in the formation of an interface between the gel and the sclera which acts 
as an escape path to flush out the blood (along with the saline, of course) (Fig. 2d). Via this mechanism, fluids 
can be removed from the operative field and visibility can be maintained even in the presence of new bleeding 
under the SPG-178.
In trabeculectomy surgery, mitomycin C can be used as an adjuvant to suppress scar formation, maintain 
blebs and help keep a low  IOP16–19. The current study reveals no significant differences in maintaining blebs and 
reducing IOP between experimental surgical groups combining SPG-178 and mitomycin C use, suggesting that 
SPG-178 elicits no adverse reactions to IOP in the eye following trabeculectomy combined with mitomycin 
C administration. Experiments were undertaken to examine whether SPG-178 in the scleral bed or the sub-
conjunctival space could impair aqueous outflow, or if it could act as a space maintainer to prevent scaring and 
enhance outflow capacity. This revealed that, in the absence of mitomycin C, operations performed with or 
without SPG-178 resulted in no difference in IOP (Supplementary Fig. S1), suggesting that SPG-178 neither acts 
as an enhancer, nor a blocker, of aqueous outflow.
When pieces of SPG-178 were deliberately placed in the anterior chamber, as might happen accidentally 
during intraocular surgery, they became cloudy and affixed to the anterior surface of the crystalline lens and to 
the corneal endothelial surface (where they had been placed). Thereafter, the SPG-178 disappeared gradually from 
the lens surface, most likely washed off by the flow of aqueous humor accompanied by the motion of the iris. SPG-
178, on the other hand, persisted longer on the corneal endothelial surface (where there is less flow of aqueous 
humor), and was still present 5-weeks post-insertion. The persistence of some residual SPG-178 gel in these 
experiments did not result in any corneal damage or loss of transparency (Fig. 3g). Nevertheless, we cannot rule 
out the possibility that accidental endothelial contact with large amounts of SPG-178 could conceivably impact 
upon endothelial function, so the use of SPG-178 may prove to be contraindicated in intraocular interventions 
or procedures that carry a high risk of perforation.
Here, we provide evidence that SPG-178 is an effective material to maintain a clear intraoperative field during 
ocular surgery, and is safe, with the caveat that the entry of large amounts of SPG-178 into the anterior chamber 
is likely to be undesirable and should be avoided. If it were to happen accidentally, the SPG-178 should be washed 
out with balanced salt solution, and ongoing experiments will ascertain how this is best achieved, with long-term 
monitoring of the endothelium using specular microscopy to be employed. Thus, the potential value of SPG-
178 gel for ophthalmic surgery has been demonstrated using an animal model of trabeculectomy for glaucoma. 
Our results hold for the short-term, with further validation needed to determine long-term safety. Additionally, 
we found that if SPG-178 enters the anterior chamber, the surgeon should try to guard against it coming into 
contact with the corneal endothelium and to implement countermeasures as mentioned above. Here, we focused 
specifically on experimental trabeculectomy to treat glaucoma, but propose that SPG-178 has potential uses in 
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other eye surgeries (such as those to treat strabismus or to excise a pterygium), and more widely outside the field 
of ophthalmology for microsurgery in which visibility within the surgical field is important.
Materials and methods
All experimental procedures adhered to the Association for Research in Vision and Ophthalmology Statement 
for the Use of Animals in Ophthalmic and Vision Research, and were approved by the Institutional Animal Care 
and Use Committee and performed according to Animal Experiment guidelines of Osaka University.
Animal use. Adult New Zealand White rabbits were used in this study. At all times, animals were housed and 
treated in accordance with the regulations of the Institute of Experimental Animal Sciences, Faculty of Medicine, 
Osaka University.
Ingress of blood into SPG‑178. To measure the ability of SPG-178 to resist the inward diffusion of blood, 
2 ml of blood from a rabbit was placed in a 35-mm disposable petri dish after which 0.5 ml of SPG-178 was 
immersed within it. Photographs were taken immediately and 2 min after placement of the SPG-178, after which 
the images were digitized using Image J (NIH)20. The area of blood ingress into the SPG-178 was quantitatively 
analyzed. The hyaluronic acid gel, Viscoat (Alcon, USA), was similarly tested as a comparator material commonly 
used in ophthalmic surgery.
The removal of blood under SPG‑178. A scleral flap (3 × 3 mm), which is a partial thickness planar 
incision in the sclera of the eye often used in ophthalmic surgery, was created unilaterally in eight buphthalmos 
 rabbits21. This induced bleeding, and in the non-SPG-178 control group of four animals the area occupied by 
blood in the bed of the scleral flap was analyzed using Image J (NIH) 30 s after the creation of the wound. In 
the treatment group, SPG-178 was applied to the scleral bed of four eyes immediately after the creation of the 
scleral flap, and the area occupied by blood 30 s after this application was quantified. SPG-178 was then applied 
to 5 regions of the sclera of one buphthalmos rabbit after which a scleral incision was created through each. 
Physiological saline was then perfused under the SPG-178 in an attempt to counteract the bleeding. The time 
from saline perfusion to regaining visibility of the sclera owing to the removal of blood was recorded.
Glaucoma filtration surgery model. For the glaucoma filtration surgery model, rabbits were anesthetized 
with an intramuscular injection of ketamine (15 mg/kg) (Daiichi Sankyo Propharma) and xylazine (10 mg/kg) 
(Bayer Yakuhin). An eyelid speculum was put in place, and the eye fixed with a corneal traction suture (7–0 
Silk, Johnson & Johnson). We then injected xylocaine (0.3–0.5  ml) under the Tenon tissue as an additional 
local anesthesia, and made a 6-mm fornix-based conjunctival flap with the Tenon’s capsule, 5 mm in length. 
Next, we made a 3 × 3  mm fornix-based scleral flap and placed 0.04% mitomycin C (Kyowa Kirin) into the 
conjunctival pocket for 3 min, which was then washed away with 50 ml of saline. Finally, we created a 2 × 1 mm 
scleral window at the limbus and performed a peripheral iridectomy, followed by a conjunctival suture with 10–0 
nylon (MANI) and the injection of 0.5 ml dexamethasone into the subconjunctiva. After surgery, 0.3% ofloxacin 
ointment (Santen Pharmaceutical) was applied to the eye. Topical administrations of 0.1% betamethasone 
sodium phosphate (SHIONOGI) and 0.5% levofloxacin hydrate ophthalmic solution (Santen Pharmaceutical) 
were applied three times a day for three days postoperatively. All surgeries were performed by the same researcher 
(K.M).
SPG‑178 use in trabeculectomy surgery. We performed a trabeculectomy with the use of SPG-178 
peptide gel in a rabbit ocular surgery model as above. Gel (0.3–0.4 g) was injected onto the surface of the anterior 
sclera so that it covered the entire scleral flap as it was made. The scleral flap was created through the gel, 
after which it was washed with saline. After confirming that no SPG-178 gel remained under the scleral flap or 
Tenon’s capsule, we created a scleral window and performed an iridectomy. SPG-178 is a peptide consisting of 13 
amino acid residues. The peptide forms an antiparallel beta sheet structure in aqueous solution via electrostatic 
interactions and a gel, SPG-178, by creating a three-dimensional network of fibers (Fig. 1c)14. SPG-178 is neutral 
and transparent and when it comes into contact with salt or a bodily fluid such as blood, it forms a boundary as 
it hardens. These properties of the SPG-178 gel mean that we can easily remove it by wiping or washing it out 
with a fluid such as balanced salt solution.
Sixteen New Zealand White rabbits underwent trabeculectomy unilaterally. Five animals underwent surgery 
with combined SPG-178 and mitomycin C use (SM group); five received surgery with mitomycin C, but not 
SPG-178 (M group); and six received a normal trabeculectomy without mitomycin C or SPG-178 (the control, 
C group). Slit-lamp microscopy, IOP measurements, and ocular coherence tomography were used to examine 
in each eye immediately after surgery and at postoperative days 1, 3, 7, 14, 21, and 28. After each examination, 
the eyes were harvested and histological analyses (HE staining) of the trabeculectomy region were performed.
Examination of SPG‑178 in the anterior chamber. In three rabbit eyes, SPG-178 was applied 
immediately adjacent to the corneal endothelium and lens using a 26-gauge needle. As a sham treatment control, 
a 26-gauge needle was brought into contact with the endothelium and lens of two rabbit eyes. The eyes were 
observed by slit-lamp microscopy on postoperative days 1, 3, 7, 14, and 35.
Statistics. Statistical analyses were performed using JMP Pro 12 software (SAS Institute Inc., Cary, NC, 
USA).
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